文献速递儿科与产科急症

非佐剂二价呼吸道合胞病毒疫苗接种与围产期结局

Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes.
PubMed 文献 · JAMA Netw Open · 2024-07-01
一句话结论回顾性队列显示孕晚期接种RSVpreF疫苗未增加早产风险(调整OR 0.87),但时间依赖模型提示妊娠期高血压疾病风险升高(HR 1.43),需进一步研究。

该回顾性观察性队列研究在纽约市2家医院开展,纳入2023年9月22日至2024年1月31日分娩、孕周≥32周的单胎妊娠孕妇2973例,其中1026例(34.5%)接种了RSVpreF疫苗。接种组早产60例(5.9%),未接种组131例(6.7%);调整混杂后早产风险未增加(调整OR 0.87,95%CI 0.62-1.20),时间依赖Cox模型亦未显示早产风险增加(HR 0.93,95%CI 0.64-1.34)。逻辑回归模型中妊娠及新生儿结局无显著差异,但时间依赖模型显示妊娠期高血压疾病风险增加(HR 1.43,95%CI 1.16-1.77)。作者认为数据支持孕晚期RSVpreF接种的安全性,但需进一步研究HDP风险。

要点

  • 孕32周及以上分娩者中,接种RSVpreF疫苗未增加早产风险:调整OR 0.87(95%CI 0.62-1.20),时间依赖模型HR 0.93(95%CI 0.64-1.34)。
  • 接种组早产60/1026(5.9%),未接种组131/1947(6.7%)。
  • 时间依赖模型显示妊娠期高血压疾病风险增加:HR 1.43(95%CI 1.16-1.77),作者认为需进一步研究。
  • 逻辑回归模型中妊娠及新生儿结局(HDP、死产、SGA、NICU入住、新生儿呼吸窘迫、黄疸/高胆红素血症、低血糖、败血症)无显著差异。
  • 15例在孕37周及以上不当接种者被归入未接种组。

适用人群与场景

  • 2023年9月22日至2024年1月31日在纽约市2家医院(同一医疗系统)分娩、孕周≥32周的单胎妊娠孕妇,共2973例。
  • 中位年龄34.9岁(IQR 32.4-37.7)。

研究设计与关键结果

  • 研究类型:回顾性观察性队列研究,2家纽约市医院,单胎妊娠孕周≥32周分娩者2973例,接种RSVpreF疫苗1026例(34.5%)。
  • 主要终点早产:接种组60/1026(5.9%) vs 未接种组131/1947(6.7%);调整OR 0.87(95%CI 0.62-1.20),时间依赖Cox模型HR 0.93(95%CI 0.64-1.34)。
  • 逻辑回归模型中妊娠及新生儿结局(HDP、死产、SGA、NICU入住、新生儿呼吸窘迫伴NICU入住、新生儿黄疸或高胆红素血症、新生儿低血糖、新生儿败血症)无显著差异。
  • 时间依赖模型显示妊娠期高血压疾病风险增加:HR 1.43(95%CI 1.16-1.77)。
  • 15例在孕37周及以上接种者被纳入未接种组。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究。
  • 局限:原文未报告局限性;作者在结论中提出需进一步研究HDP风险。

对床旁实践的改变

  • 作者认为这些数据支持孕晚期RSVpreF疫苗接种的安全性,但需进一步研究HDP风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: A nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF [Pfizer]) protein subunit vaccine was newly approved and recommended for pregnant individuals at 32 0/7 to 36 6/7 weeks' gestation during the 2023 to 2024 RSV season; however, clinical vaccine data are lacking.

OBJECTIVE: To evaluate the association between prenatal RSV vaccination status and perinatal outcomes among patients who delivered during the vaccination season.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational cohort study was conducted at 2 New York City hospitals within 1 health care system among patients who gave birth to singleton gestations at 32 weeks' gestation or later from September 22, 2023, to January 31, 2024.

EXPOSURE: Prenatal RSV vaccination with the RSVpreF vaccine captured from the health system's electronic health records.

MAIN OUTCOME AND MEASURES: The primary outcome is preterm birth (PTB), defined as less than 37 weeks' gestation. Secondary outcomes included hypertensive disorders of pregnancy (HDP), stillbirth, small-for-gestational age birth weight, neonatal intensive care unit (NICU) admission, neonatal respiratory distress with NICU admission, neonatal jaundice or hyperbilirubinemia, neonatal hypoglycemia, and neonatal sepsis. Logistic regression models were used to estimate odds ratios (ORs), and multivariable logistic regression models and time-dependent covariate Cox regression models were performed.

RESULTS: Of 2973 pregnant individuals (median [IQR] age, 34.9 [32.4-37.7] years), 1026 (34.5%) received prenatal RSVpreF vaccination. Fifteen patients inappropriately received the vaccine at 37 weeks' gestation or later and were included in the nonvaccinated group. During the study period, 60 patients who had evidence of prenatal vaccination (5.9%) experienced PTB vs 131 of those who did not (6.7%). Prenatal vaccination was not associated with an increased risk for PTB after adjusting for potential confounders (adjusted OR, 0.87; 95% CI, 0.62-1.20) and addressing immortal time bias (hazard ratio [HR], 0.93; 95% CI, 0.64-1.34). There were no significant differences in pregnancy and neonatal outcomes based on vaccination status in the logistic regression models, but an increased risk of HDP in the time-dependent model was seen (HR, 1.43; 95% CI, 1.16-1.77).

CONCLUSIONS AND RELEVANCE: In this cohort study of pregnant individuals who delivered at 32 weeks' gestation or later, the RSVpreF vaccine was not associated with an increased risk of PTB and perinatal outcomes. These data support the safety of prenatal RSVpreF vaccination, but further investigation into the risk of HDP is warranted.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Son M, Riley LE, Staniczenko AP, et al. Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes. JAMA Netw Open. 2024. PMID: 38976271. doi:10.1001/jamanetworkopen.2024.19268

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。